Our data demonstrates that Tzm linked to PEG-PHis micelles is highly efficient as a therapeutic agent in the case of our TNBC pre-clinical cancer models, impairing metastasis even at lower doses than clinically used for Her2+ patients. The gene discussed is ERBB2; the disease is cancer.